PHASEBIO PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt SecuritiesIndenture • December 27th, 2019 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • New York
INDENTURE, dated as of [●], 20__, among PHASEBIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
PHASEBIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFWarrant Agreement • December 27th, 2019 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PHASEBIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
PHASEBIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • December 27th, 2019 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between PHASEBIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
60,000,000 Shares Common Stock ($0.001 par value) Equity Distribution AgreementTerms Agreement • December 27th, 2019 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • New York
PhaseBio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with each of Citigroup Global Markets Inc. and William Blair & Company, L.L.C. (each a “Manager”, and together, the “Managers”) as follows:
